Denis Chem Lab Ltd
Denis Chem Lab Ltd is a pharmaceutical company engaged in the development, manufacturing, and sale of generic and branded pharmaceutical products.
Business. Denis Chem Lab Ltd (DECH.BO) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in India and is primarily listed on the Bombay Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level as a participant in the broader pharmaceuticals and medical research sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Denis Chem Lab Ltd (DECH.BO) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in India and is primarily listed on the Bombay Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level as a participant in the broader pharmaceuticals and medical research sector.
Denis Chem Lab Ltd maintains a strong liquidity position, with a current ratio of 2.55 and cash and equivalents amounting to INR 234.81 million, which represents 21.5% of total assets. The company's liquidity FPT (Fundamental Price Target) is stable, indicating no immediate pressure on cash reserves.
Profitability metrics show a return on equity (ROE) of 3.4% and a return on assets (ROA) of 2.5%, both below the industry median for pharmaceutical firms. The operating margin of 8.4% (calculated from operating income of INR 33.30 million on revenue of INR 398.55 million) is also below the sector average, suggesting room for improvement in cost management and pricing power.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory shifts, particularly in India where the company is based.
Looking ahead, Denis Chem Lab Ltd is projected to grow revenue by 12.3% in the current fiscal year and 9.1% in the next, driven by expansion in its product portfolio and market penetration. However, the growth trajectory is moderate compared to peers, and the company has not disclosed specific R&D or capex plans to support this expansion.
Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.01, indicating a conservative capital structure. No dilution sources were identified in recent filings, and the dilution potential remains low.
Recent events include the filing of the latest annual report, which disclosed no material changes in business strategy or regulatory exposure. The company has not issued new shares in the past 12 months, and no ATM or shelf registration is currently active.
- Denis Chem Lab Ltd maintains a conservative capital structure with low debt and strong liquidity.
- Profitability metrics are below industry medians, indicating potential inefficiencies in operations or pricing.
- Revenue is concentrated in a single business segment with no geographic diversification.
- The company is projected to grow revenue by 12.3% in the current fiscal year, but growth is moderate compared to peers.
- No immediate liquidity or dilution risks are present, and the company has not issued new shares recently.
Bull / Bear case
Generated · model-assistedCash conversion ratio of 6.45 is best-in-class compared to the cohort median of 0.95, showing exceptional cash generation.
Return on equity of 3.4% beats the pharmaceutical sector median of 2.9%, reflecting efficient use of shareholder capital.
Debt-to-equity ratio of 0.01 is well below the cohort median of 0.18, indicating a very conservative capital structure.
Revenue growth slowed to just 3.3% year-over-year, suggesting weakening top-line momentum compared to historical trends.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Denis Chem Lab Ltd Market data — financials · 2026-05-27